| Fecha | Hora | Fuente | Título | Símbolo | Compañía |
| 06/11/2019 | 16:03 | Edgar (US Regulatory) | Quarterly Report (10-q) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 06/11/2019 | 09:30 | Edgar (US Regulatory) | Unknown (sec Staff) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 29/08/2019 | 15:31 | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 10/06/2019 | 08:32 | Edgar (US Regulatory) | Certification by the Exchange Approving Securities for Listing (cert) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 07/06/2019 | 15:56 | Edgar (US Regulatory) | Securities Registration (section 12(b)) (8-a12b) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 07/06/2019 | 15:41 | Edgar (US Regulatory) | Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme... | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 07/06/2019 | 15:22 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 28/05/2019 | 15:10 | GlobeNewswire Inc. | Rexahn Announces Move to Nasdaq | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 13/05/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 29/04/2019 | 15:45 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 16/04/2019 | 07:00 | GlobeNewswire Inc. | Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 12/04/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Effects 1-for-12 Reverse Stock Split | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 10/04/2019 | 15:07 | GlobeNewswire Inc. | Rexahn Announces Reverse Stock Split | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 27/03/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 11/03/2019 | 05:32 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 08/03/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Pharmaceuticals Reports 2018 Financial Results | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 07/03/2019 | 15:52 | Edgar (US Regulatory) | Annual Report (10-k) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 04/03/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line... | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 01/03/2019 | 16:58 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 01/03/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 19/02/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 14/02/2019 | 12:41 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 06/02/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 05/02/2019 | 05:03 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 04/02/2019 | 16:50 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 04/02/2019 | 07:00 | GlobeNewswire Inc. | Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 24/01/2019 | 16:16 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 23/01/2019 | 08:00 | GlobeNewswire Inc. | Rexahn Announces Pricing of Public Offering of Common Stock and Warrants | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 22/01/2019 | 15:42 | GlobeNewswire Inc. | Rexahn Announces Proposed Public Offering of Common Stock and Warrants | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |
| 22/01/2019 | 06:30 | GlobeNewswire Inc. | Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium | AMEX:RNN | Rexahn Pharmaceuticals, Inc. |